{
    "clinical_study": {
        "@rank": "156617", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I. Evaluate the efficacy and toxicity of glucocerebrosidase enzyme therapy in patients with\n      Gaucher disease."
        }, 
        "brief_title": "Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease", 
        "condition": "Gaucher's Disease", 
        "condition_browse": {
            "mesh_term": "Gaucher Disease"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients are treated with intravenous glucocerebrosidase every 2 weeks.  The dose is based\n      on clinical severity of disease and response to therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Gaucher disease with glucocerebrosidase deficiency confirmed\n        by enzymatic or molecular assay At least 3 organ systems affected, based on the following\n        criteria: Anemia Thrombocytopenia Organomegaly Bone deterioration on radiograph Pulmonary\n        compromise Symptoms compromise daily activities or risk longevity No neurologic disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "24", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004293", 
            "org_study_id": "199/11725", 
            "secondary_id": "UPITTS-M1230"
        }, 
        "intervention": {
            "intervention_name": "glucocerebrosidase", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Gaucher's disease", 
            "inborn errors of metabolism", 
            "rare disease", 
            "sphingolipidoses"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "contact": {
                "last_name": "John Barranger", 
                "phone": "412-624-4623"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15260"
                }, 
                "name": "University of Pittsburgh"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "John Barranger", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004293"
        }, 
        "source": "National Center for Research Resources (NCRR)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "November 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2003"
    }, 
    "geocoordinates": {
        "University of Pittsburgh": "40.441 -79.996"
    }
}